NewAmsterdam Pharma Co N.V.(NAMS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,931 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
NAMS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for NewAmsterdam Pharma Co N.V. (NAMS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAMS at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,931 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NewAmsterdam Pharma Co N.V. reports quarterly revenue of $3.7M, net income of $-64.1M, free cash flow of $-39.3M. Top institutional holders of NAMS by reported 13-F value include Frazier Life Sciences Management, L.P., Capital World Investors, FMR, based on the most recent SEC filings. NAMS trades on the Nasdaq exchange and files with the SEC under CIK 1936258. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewAmsterdam Pharma Co N.V. directly from SEC EDGAR. NewAmsterdam Pharma Co N.V.'s 13F Pro composite quality score has ranged between 8 and 30 since 2026, currently 8.2 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$3.7M
Net Income
Q2 2026
$-64.1M
Free Cash Flow
Q2 2026
$-39.3M
ROIC
Q2 2026
-41.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-50.6% YoYNet Income
+15.6% YoYOperating Income
-28.0% YoYEPS (Diluted)
+32.8% YoYTotal Assets
-11.0% YoYOp. Cash Flow
+6.8% YoYFree Cash Flow
+7.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.5M -50.6% | $45.6M +223.4% | $14.1M -86.3% | $102.7M | — | — |
| Net Income | $-203.8M +15.6% | $-241.6M -36.5% | $-176.9M -681.7% | $-22.6M +45.8% | $-41.8M | — |
| Operating Income | $-225.7M -28.0% | $-176.3M +3.6% | $-183.0M -5043.9% | $-3.6M +89.8% | $-35.0M | — |
| EPS (Diluted) | $-1.72 +32.8% | $-2.56 -19.1% | $-2.15 -80.7% | $-1.19 +68.8% | $-3.81 | — |
| Total Assets | $769.3M -11.0% | $864.6M +149.1% | $347.1M -34.7% | $531.6M +789.2% | $59.8M | — |
| Operating Cash Flow | $-147.8M +6.8% | $-158.6M -12.3% | $-141.2M -1424.1% | $10.7M +136.1% | $-29.5M | — |
| Free Cash Flow | $-148.0M +7.0% | $-159.2M -12.7% | $-141.2M -1452.4% | $10.4M +135.4% | $-29.5M | — |
Get alerted when NAMS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NewAmsterdam Pharma Co N.V. including:
Top Institutional Holders of NAMS
Frazier Life Sciences Management, L.P.
$613.0M18,088,902 shCapital World Investors
$414.5M12,230,557 shFMR LLC
$350.4M10,339,663 shRA CAPITAL MANAGEMENT, L.P.
$323.7M9,550,191 shFCPM III SERVICES B.V.
$287.7M8,490,353 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$144.5M4,264,789 shVIKING GLOBAL INVESTORS LP
$142.5M4,203,567 shBain Capital Life Sciences Investors, LLC
$129.0M3,806,566 shMAVERICK CAPITAL LTD
$110.7M3,267,802 shDuquesne Family Office LLC
$104.0M3,070,146 sh
| Fund | Value | Shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | $613.0M | 18,088,902 |
| Capital World Investors | $414.5M | 12,230,557 |
| FMR LLC | $350.4M | 10,339,663 |
| RA CAPITAL MANAGEMENT, L.P. | $323.7M | 9,550,191 |
| FCPM III SERVICES B.V. | $287.7M | 8,490,353 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $144.5M | 4,264,789 |
| VIKING GLOBAL INVESTORS LP | $142.5M | 4,203,567 |
| Bain Capital Life Sciences Investors, LLC | $129.0M | 3,806,566 |
| MAVERICK CAPITAL LTD | $110.7M | 3,267,802 |
| Duquesne Family Office LLC | $104.0M | 3,070,146 |
Companies Similar to NAMS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Dianthus Therapeutics, Inc. /DE/
Equillium, Inc.
Aclaris Therapeutics, Inc.
Wave Life Sciences, Inc.
Monte Rosa Therapeutics, Inc.
Nurix Therapeutics, Inc.
uniQure N.V.
Zymeworks Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NAMS on your watchlist
Track score changes the day NewAmsterdam Pharma Co N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NAMS a good stock to buy?
13F Pro's AI-powered analysis of NewAmsterdam Pharma Co N.V. (NAMS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NAMS are available on the NAMS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NAMS is classified as a mid company.
Which hedge funds own NAMS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NAMS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NewAmsterdam Pharma Co N.V.'s investment landscape.